Impact of interventions to prevent and manage preeclampsia and eclampsia on stillbirths

Mehnaz Jabeen, Mohammad Yawar Yakoob, Aamer Imdad, Zulfiqar A Bhutta*

Abstract

Background: Pre-eclampsia and Eclampsia are relatively common complications of pregnancy, leading to considerable maternal and fetal mortality and morbidity. We sought to review the effect of aspirin, calcium supplementation, antihypertensive agents and magnesium sulphate on risk stillbirths.

Methods: A systematic literature search was conducted to identify studies evaluating the above interventions. We used a standardized abstraction and grading format and performed meta-analyses where data were available from more than one studies. The estimated effect on stillbirths was determined by applying the standard Child Health Epidemiology Reference Group (CHERG) rules for multiple outcomes. For interventions with insufficient evidence for overall effect, a Delphi process was undertaken to estimate effectiveness.

Results: We identified 82 relevant studies. For aspirin, magnesium sulphate and use of antihypertensive we found an insignificant decrease in stillbirth and perinatal mortality. For calcium supplementation, there was a borderline significant reduction in stillbirths (RR 0.81, 95 % CI 0.63-1.03). We undertook a Delphi consultation among experts to assess the potential impact of a package of interventions for the management of pre-eclampsia and eclampsia (antihypertensive, magnesium sulphate and C-section if needed). The Delphi process suggested 20% reduction each in both antepartum and intrapartum stillbirths with the use of this package.

Conclusions: Despite promising benefits of calcium supplementation and aspirin use cases on maternal morbidity and eclampsia in high risk cases, further work is needed to ascertain their benefits in relation to stillbirths. The Delphi process undertaken for assessing potential impact of a package of interventions indicated that this could be associated with 20% reduction in stillbirths, for input into LiST.

Background

Hypertensive disease of pregnancy (HDP) is one of the most common complications of pregnancy, occurring in 5-8% of the pregnancies [1]. Hypertensive disorders are the second most common cause of maternal deaths worldwide [2]. There are several major categories of hypertensive disorders in pregnancy ranging from mild to moderate rise in blood pressure without proteinuria [usually called pregnancy induced hypertension (PIH)], preeclampsia (hypertension with proteinuria), severe preeclampsia and eclampsia [3]. Maternal hypertension, even of the mild to moderate category, can lead to adverse perinatal outcomes like low birth weight, prematurity, stillbirth and intrauterine growth retardation [4]. A population-based study of 57 million singleton live- and stillbirths has shown that pregnancy induced hypertension (PIH) is associated with increased risk of stillbirth and neonatal mortality [5]. The risk of stillbirth was higher in women having their second or higher order births [(Odds Ratio (OR) =2.24, 95% confidence interval (CI) =2.11-2.37)] compared with women having their first birth (OR=1.52, 95% CI=1.40-1.64).

Detection and prevention of maternal hypertensive disorders is important in order to avoid morbidity and mortality associated with them [6]. Potential interventions for reducing the risk of preeclampsia include calcium and aspirin used for prevention and use of anti-hypertensive drugs and magnesium sulphate for management of preeclampsia/eclampsia. A 17% reduction in the risk of preeclampsia was noted with the use of antiplatelet agents – mostly low dose aspirin - in pregnant women at risk of preeclampsia (RR 0.83 95% CI 0.77-0.89) [7]. A Cochrane review [8] that included 13 randomized trials...
comprising 15,730 women has shown that calcium supplementation during pregnancy reduces the incidence of preeclampsia by 55% [Relative risk (RR) =0.45 95% confidence interval (CI) 0.31-0.65] and that of gestational hypertension by 35% [RR=0.65, 95% CI 0.53-0.81]. The reduction in the risk of preeclampsia was greatest for women at high risk of developing preeclampsia (RR 0.22, 95% CI 0.12-0.42), and for those with low baseline intake of calcium (RR 0.36, 95% CI 0.20-0.65). A variety of antihypertensive agents including beta-blockers like labetalol [9,10], atenolol [11,12], oxeprenolol [13]; calcium-channel blockers like isradipine [14], nifedipine [15,16]; and other antihypertensive drugs like methyldopa (an alpha-blocker) [17-19] have been shown to be effective in controlling blood pressure during pregnancy. Magnesium sulphate (MgSO4) supplementation has been shown to be effective for prevention of eclampsia in pre-eclamptic women [20]. A Cochrane review [21] that included six trials for MgSO4 analysis has shown that compared with placebo or no anticonvulsant, MgSO4 reduced the risk of eclampsia by 59% [RR 0.41, 95% CI 0.29 to 0.58].

The purpose of this paper was to review the effect of calcium supplementation, aspirin, antihypertensive agents, and magnesium sulphate on stillbirths and perinatal mortality related to maternal hypertensive disorders. This paper is a part of series of papers for the Lives Saved Tool (LiST). The process of generating a point estimate for efficacy of an intervention involves qualitative evaluation of available evidence according to Grading of Recommendations, Assessment, Development and Evaluation (GRADE) criteria [22] and quantitative measure according to Child Health Epidemiology Reference Group (CHERG) rules [23]. For more details of the review methods, the adapted GRADE approach or the LiST model see the methods paper [23] and other articles in this supplement.

Methods

We systematically reviewed all published literature from 1957 to June 2010 to identify studies that reported the effect of calcium supplements, aspirin, antihypertensive drugs or magnesium sulphate on stillbirths and perinatal mortality as outcomes amongst pregnant women. As per CHERG guidelines [23], we searched PubMed, the Cochrane Library and all WHO regional databases and included publications available in any language [23].

Two search strategies were used as follows:

1) (aspirin OR antiplatelet OR antihypertensive* OR “beta-blocker*” OR “calcium channel blocker*” OR “alpha-blocker*” OR “magnesium sulphate”) AND (pregnancy or maternal) AND (stillbirth* OR “perinatal mortality” OR “fetal death*” OR eclampsia OR “severe preeclampsia” OR “intrauterine death” OR “preeclampsia OR “preeclampsia”).

2) “Calcium” AND “pregnancy” AND (“Hypertension” OR “preeclampsia” OR “blood pressure” OR “Stillbirth” OR “Intrauterine death”).

Every effort was made to gather unpublished data when reports were available for full abstraction. Previous reviews were also hand-searched for relevant studies not picked up in the primary literature search [3,24-26]

Inclusion/exclusion criteria

We included randomized and quasi-randomized controlled trials that evaluated the following as an intervention: calcium supplements, aspirin with or without other antiplatelet agents, antihypertensive agents of any category, and magnesium sulphate. Studies were included if they had an identical control group that was given either placebo or no treatment. The studies were selected irrespective of the dose used. For calcium, only those studies were included in which baseline calcium intake of participants was low as calcium supplementation during pregnancy is effective only in population with low calcium intake. We excluded any studies reporting only before-after comparisons as well as observational studies and in addition we excluded those studies that did not report outcomes of interest for this review.

Abstraction, analysis, and summary measures

All studies that met the final inclusion and exclusion criteria were double-data abstracted into a standardized form for each outcome. We extracted the data for study design; location; population; methods; limitations; assessment of blinding, allocation concealment; and outcomes of interest. Each study was assessed and graded according to the CHERG adaptation of the GRADE technique. Each study was assigned a final quality grade of ‘high’ ‘moderate’ ‘low’ or ‘very low’ on the basis of strengths and limitations of study [22,23]. Studies receiving a grade of ‘very low’ were excluded from the analysis. The grading of overall (pooled) evidence was based on three components: (1) the volume and consistency of the evidence; (2) the size of the pooled effect and (3) the strength of the statistical evidence reflected in the p-value [23]. A similar grading of ‘high’ ‘moderate’ ‘low’ and ‘very low’ was used for grading the overall evidence indicating the strength of an effect of the intervention on specific health outcome [23].

We undertook meta-analyses where data were available from more than one study for an outcome and reported Mantel-Haenszel pooled relative risks and corresponding 95% confidence intervals. The primary outcome of interest was stillbirth. Statistical heterogeneity in the pooled data was assessed by visual inspection of overlap of confidence intervals and P-value (P < 0.10 was taken to mean substantial heterogeneity).
The assessment of statistical heterogeneity in the pooled analysis was done by visual inspection i.e. the overlap of the confidence intervals among the studies, Chi square (P-value) of heterogeneity in the meta-analyses and I² statistics. A low P value (less than 0.10) or a large chi-squared statistics relative to its degree of freedom and I² values greater than 50% were taken as substantial and high heterogeneity. In situations of substantial or high heterogeneity being present, causes were explored by sensitivity analysis and random effects model were used.

**Results**

We identified 2069 titles from the first search strategy and 1022 titles from the second, in searches conducted in databases including PubMed and the Cochrane Library (Figure 1). After initial screening of these titles and abstracts, we reviewed 121 papers to identify outcomes of interest and included 82 papers in the final database. All the included studies were blinded, randomized, controlled treatment trials. The detailed data extraction with the limitation of studies is shown in Additional File 1. In tables 1, 2, 3, 4, we report the quality assessment of studies of each intervention by outcome, as well as results from corresponding meta-analyses.

**Aspirin in high-risk pregnancy**

To estimate the effect of aspirin in high-risk pregnancies for prevention of preeclampsia, we found 21 studies which reported data on the effect of aspirin alone on stillbirths [1,4,9,12,13,15-19,27-37] and 3 studies reporting combined effects of aspirin and dipyramide on stillbirths [38-40]. A total of 13 studies reported perinatal mortality [1,4,15,17,27,29,31,33,35,36,39,41-43] (Table 1). The effect of aspirin alone showed no significant effect on risk of stillbirths (RR= 1.15; 95% CI: 0.88 to 1.49) (Figure 2). Combining studies of aspirin with dipyramide with aspirin alone yielded similar results (RR= 1.06; 95% CI: 0.82 to 1.37).

**Calcium supplementation in low-intake population**

To estimate the effect of calcium supplementation in pregnant women in low-intake population, we found 3 studies which reported data on stillbirths, [55-57] and 4 studies which reported perinatal mortality (Table 2). Our analysis suggested that calcium supplementation during pregnancy could potentially reduce stillbirths by 19%, however results were not statistically significant (RR 0.81, 95 % CI 0.63-1.03) (Figure 3). These data suggest the need for further large scale studies of calcium supplementation in populations with specific assessment of stillbirth outcomes.

**Antihypertensive agents in pregnancy with mild to moderate hypertension**

To estimate the effect of antihypertensive agents in pregnant women with mild to moderate hypertension, we found 18 studies which reported data on stillbirths [10,14,58-73] and twenty studies which reported data on perinatal mortality [14,58,60,61,63-66,68,69,71-80] (Table 3). The effect of antihypertensive drugs showed no effect for stillbirths (RR= 1.14; 95% CI: 0.60 to 2.17) (Figure 4).

**Magnesium sulphate in pregnancy with preeclampsia**

To estimate the effect of magnesium sulphate for pregnancies with preeclampsia versus placebo or no treatment, we found 3 studies which reported data on stillbirths [82-84], 2 studies which reported perinatal mortality [82,83] (Table 4). There was no impact of use of magnesium sulphate on stillbirths (RR= 0.99; 95% CI: 0.87 to 1.12) (Figure 5).

**Delphi process for establishing expert consensus**

As there was no convincing evidence in favor or against of use of antihypertensive and magnesium sulphate with respect to stillbirths, we sought expert consensus via the Delphi method [23]. The panel invited to participate were experts belonging to six WHO regions (South Asia, Africa, Western Europe, Eastern Europe, North America, and Australia) and a range of disciplines including maternal health, public health, obstetrics/gynecology, and midwifery. 33 experts agreed to participate in the Delphi process. The questionnaire was developed by MYY and ZAB, and refined after several rounds of pilot testing. The questionnaire was sent by email and included the background and aims of the Delphi and estimates of effect that were available from the literature for different scenarios. The median response and range were determined for each question. Consensus was defined a priori as an interquartile range in responses of not more than 30% for each question and in this instance; consensus was achieved after first iteration. The Delphi consensus suggested median effect of 20% reduction in antepartum and intrapartum stillbirths with the HDP package with interquartile ranges of 10-30% and 10-40% respectively (Figure 6).

**Discussion**

Over 2.5 million babies are born dead each year, making stillbirth one of the most important adverse outcomes of pregnancy [88]. Hypertension during pregnancy is a risk factor for stillbirth [89-91] especially in low socioeconomic settings [92]. The two most commonly used preventive measures are; use of aspirin in high risk pregnancies and calcium supplementation in populations with low calcium intake [20]. In this review we have
1st search strategy
Total abstracts= 2069

Records after duplicates removed (n = 3085)

Records screened (n = 3085)

Full-text articles assessed for eligibility (n = 121)

Studies included in The review: (n = 82)

Calcium (n=4)

Aspirin (n=46)

Antihypertensive agents (n=26)

MgSO4 (n=6)

2nd search strategy
Total abstracts= 1022

Records excluded (n = 2694)

Full-text articles excluded (n = 19)

Figure 1 Flow chart for study selection.

| Table 1 Quality assessment of trials of aspirin alone in high-risk pregnancies for prevention of preeclampsia |
|---|---|---|---|---|
| No of studies (ref) | Design | Limitations | Consistency | No of events |
| Stillbirths: LOW outcome specific quality |
| 21 | RCT | High non-compliance rate, Small sample size, Placebo not used, Not double-blinded. | Consistent; Low heterogeneity (p=0.62); Results statistically insignificant | 1 study in developing country | Yes | 113 | 95 | 1.15 (0.88, 1.49) |

Perinatal mortality: MODERATE/LOW outcome specific quality |
| 13 | RCT | Low compliance; Small sample size | Consistent; Low heterogeneity (p=0.39); Results statistically insignificant | 3 studies in developing countries | Yes | 187 | 209 | 0.89 (0.74, 1.08) |
found that use of aspirin was not associated with a decrease in stillbirths (RR= 1.15; 95% CI: 0.88 to 1.49). Results of this review are different from that of Cochrane review [25] on the topic (aspirin) as data for stillbirth were pooled with miscarriages in the Cochrane review. The combined results in the Cochrane review also showed no effect of aspirin (RR=0.96; CI= 0.78 to 1.18). In any case, despite having a protective effect against pre-eclampsia, there was no convincing evidence to recommend use of ‘aspirin alone’ for reduction of stillbirths for input to the Live Saved Tool (LiST).

Analysis in this review has shown that calcium supplementation during pregnancy reduced stillbirths by 19%; however results were not statistically significant (RR 0.81, 95% CI 0.63-1.03). A Cochrane review on effectiveness of calcium supplementation during pregnancy [24] also showed a statistically insignificant 30% reduction in the outcome of stillbirths or death before discharge (RR 0.70, 95% CI 0.69 to 1.09). There was however 55% reduction in risk of preeclampsia (RR 0.45, 95% CI 0.31 to 0.65). Although the evidence in support of calcium supplementation for women at risk of low intake is robust [24], further research is needed with assessment of the full range of pregnancy outcomes before this can be recommended for inclusion in the LiST model for prevention of stillbirth.

This review has shown that use of antihypertensive drugs has no effect on incidence of stillbirths, which is similar to the results from the Cochrane review (RR=1.14 CI=0.60 to 2.17) [3]. It should be noted that most data included in this review for aspirin, antihypertensive agents and magnesium sulphate was from developed countries, as data from developing countries was scarce. Several studies had too small a sample size to be able to detect differences in stillbirths. Moreover, noncompliance rates to the aspirin were as high as 20% in certain studies. In a few studies, a no-treatment group was used as a control group instead of a placebo group, which may have affected the results.

Given these limitations of the data, we also used the Delphi process to generate an impact estimate for impact of a package of interventions that involve detection and management of hypertensive disease of pregnancy. The package included use of an appropriate antihypertensive, magnesium supplementation in case of

| Quality Assessment | Directness | Summary of Findings |
|--------------------|------------|---------------------|
| No. of studies (Ref) | Design Limitations Consistency Generalizability to Population of Interest Generalizability to intervention of Interest Events in Intervention group Events in control group Relative Risk (95% CI) |

| Stillbirth: Moderate outcome specific quality |
|---------------------------------------------|
| 3 RCT None Consistent (I² = 0) Yes all from developing countries Dose of calcium supplementation ranged from 1.5-2 g/day in all the included studies 117 145 0.81 (0.63-1.03) |

| Perinatal mortality: Low outcome specific quality |
|-----------------------------------------------|
| 4 RCTs None Consistent (I² = 0) Yes All from developing countries Dose of calcium supplementation ranged from 1.5-2 g/day in all the included studies 154 179 0.86 (0.70-1.07) |

Table 3 Quality assessment of trials of antihypertensive agents in pregnancies with mild to moderate hypertension

| Quality Assessment | Directness | Summary of Findings |
|--------------------|------------|---------------------|
| No. of studies (Ref) | Design Limitations Consistency Generalizability to population of interest Generalizability to intervention of interest Intervention Control Relative Risk (95% CI) |

| Stillbirths: MODERATE/LOW outcome specific quality |
|-----------------------------------------------|
| 18 RCT Small sample size, Placebo not used Consistent; Low heterogeneity (p=0.93); Results statistically insignificant 3 studies in developing countries Yes 18 16 1.14 (0.60, 2.17) |

| Perinatal mortality: MODERATE/LOW outcome specific quality |
|-----------------------------------------------|
| 20 RCT Small sample size, Placebo not used Consistent; Low heterogeneity (p=0.97); Results statistically insignificant 3 studies in developing countries Yes 30 82 0.90 (0.60, 1.54) |
Table 4 Quality assessment of trials of magnesium sulphate in pregnancies with preeclampsia

| Quality Assessment | Directness | Summary of Findings |
|--------------------|------------|---------------------|
| No of studies (ref) | Design | Limitations | Consistency | Generalizability to population of interest | Generalizability to intervention of interest | Intervention | Control | Relative Risk (95% CI) |
| Stillbirths: HIGH/MODERATE outcome specific quality |
| 3 | RCT | None | Consistent; Low heterogeneity (p=0.34); Results statistically insignificant | 2 studies in developing countries | Yes | 424 | 426 | 0.99 (0.87, 1.12) |

Perinatal mortality: HIGH/MODERATE outcome specific quality |
| 2 | RCT | None | Consistent; Low heterogeneity (p=0.45); Results statistically insignificant | 1 study in developing country | Yes | 538 | 541 | 0.98 (0.88, 1.10) |

Page 6 of 11

Figure 2 Forest plot for the effect of aspirin on stillbirths.
preeclampsia/eclampsia and availability of C-section when required. The selection of this package was based on the fact these interventions are accepted standards of care for management of preeclampsia/eclampsia [6]; however their role in prevention of stillbirths has not been extensively studied as described above. We therefore contacted experts in the field (total 33) and asked their opinion on how effective this package of intervention could be to reduce incidence of stillbirths. The results yielded a reduction of 20 % in antepartum and intrapartum stillbirths. It should be noted that this evidence is based on expert’s opinion only and considered as the weakest evidence in the CHERG’s methods of evaluation of effectiveness of an intervention [23]. We therefore recommend that future research should focus on better understanding of the role of detection and

| Study or Subgroup | Calcium | Placebo | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|---------|---------|-------------------------------|
|                   | Events  | Total   | Events | Total   | Weight |                       |
| Belizan 1981      | 569     | 7568    | 567    | 7       | 4.9%   | 0.97 [0.29, 2.59]       |
| Kumar 2009        | 273     | 3251    | 251    | 5       | 3.8%   | 1.10 [0.34, 3.57]       |
| Yilmaz 2006       | 4151    | 4197    | 133    | 1       | 91.8%  | 0.79 [0.32, 1.02]       |
| **Total (95% CI)**| **5012**| **5015**| **100.0%** | 0.81 [0.63, 1.03] |

Heterogeneity: Ch² = 4.93, df = 11 (P = 0.93); I² = 0%
Test for overall effect: Z = 1.74 (P = 0.08)

Figure 3 Forest plot for the effect of calcium supplementation on stillbirths.
management of gestational hypertensive disorders in prevention of stillbirths. It is possible that a package of interventions has an effect that is greater than the individual components and the inclusion of, for example, C Section, may explain the effect attributed to the package as a whole by the experts. Finally, it is possible the experts were unaware of negative summary data of components of the package.

Conclusion
In conclusion, aspirin and calcium play a significant role in prevention of preeclampsia however their role in reducing stillbirths is not well established. Antihypertensive and magnesium sulphate supplementation for hypertensive disorders in pregnancy reduce morbidity and mortality associated with these disorders however their role in reducing stillbirths is not clear. Based on expert’s opinion a package of detection and management of gestational hypertensive disorders (Antihypertensive, MgSO4 and C-

Additional material

Acknowledgements
This work was supported in part by a grant to the US Fund for UNICEF from the Bill & Melinda Gates Foundation (grant 43386) to “Promote evidence-based decision making in designing maternal, neonatal and child health interventions in low- and middle-income countries.”

Authors’ contributions
Professor Zulfiqar A Bhutta developed the review parameters and secured support. Drs Mehnaz Jabeen, Yawar Yakoob and Aamer Imdad undertook the literature search, data extraction and analysis under the supervision of Professor Bhutta. Professor Bhutta gave advice in all the aspects of the project and was the overall supervisor.

Competing interests
The authors declare no conflict of interest

Published: 13 April 2011

References
1. Yu CKH, P AT, Parra M, Palma Das R, Nicolaides KH: Randomized controlled trial using low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine Doppler at 23 weeks gestation. Ultrasound in Obstetrics & Gynecology 2003, 22:233-239.
2. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF: WHO analysis of causes of maternal death: a systematic review. Lancet 2006, 367(9516):1066-1074.
3. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ: Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2007, :1. CD002252.
4. Italian Study of Aspirin in Pregnancy: Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. Lancet 1993, 341(8842):396-400.
5. Ananth CV, Basso O. Impact of pregnancy-induced hypertension on stillbirth and neonatal mortality. *Epidemiology* 2010, 21(1):118-123.

6. Norwitz ER, Repie KE. *Preeclampsia prevention and management*. *J Soc Gynecol Invest* 2000, 7(1):21-36.

7. Ronsmans C, Campbell O. Quantifying the fall in mortality associated with interventions related to hypertensive diseases of pregnancy. *BMC Public Health* 2010.

8. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. *Cochrane Database Syst Rev* 2010, 8:CD001059.

9. Vaino M, Kujanu E, Ios-Mustajarvi M, Maapaa J. Low dose acetylsalicyclic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. *BJOG* 2002, 109(2):161-167.

10. Wide-Svensson DH, Ingemarsson I, Lunell NO, Forman A, Sjakaj K, Lindsberg B, Lindeberg S, Marsal K, Andersson KE. Calcium channel blockade (isradipine) in treatment of hypertension in pregnancy: a randomized placebo-controlled study. *Am J Obstet Gynecol* 1995, 173(3 Pt 1):827-878.

11. Tulppala M, Marttunen M. Sodenstroem-Anttila V, Fouldla T, Allus K, Palouso T, Ylikorkala O. Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on pregnancy and thromboxane A2 production. *Hum Reprod* 1997, 12(7):1567-1572.

12. Uzan S, Beaufils M, Breat G, Bazin B, Capitant C, Paris J. The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. *N Engl J Med* 1989, 321(6):351-356.

13. Sibai BM, Mabie WC, Shamsa F, Villar MA, Anderson GD. A comparison of no medication versus methylpoda or labetalol in chronic hypertension during pregnancy. *Am J Obstet Gynecol* 1990, 162(4):960-966, discussion 966-967.

14. Sibai BM, Carusi SN, Thorn E, Kiebanagan M, McNeillls D, Rocoo L, Paul RH, Romero R, Witter F, Rosen M, et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. *N Engl J Med* 1993, 329(17):1213-1218.

15. Wallenburg HC, Dekker GA, Makovitz JW, Rottman H. Effect of low-dose aspirin on vascular refractoriness in angiotensin-sensitive primigravid women. *Am J Obstet Gynecol* 1991, 164(5 Pt 1):1169-1173.

16. Subtil D, Goeusse P, Puech F, Lequeun P, Biausque S, Breat G, Uzan S, Marquis P, Parmenter D, Churelet A. Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: the Essai Regional Aspirine Mere-Enfant study (Part 1). *Br J Obstet Gynaecol* 2003, 110(5):473-494.

17. Vinikla L, Hartikainen-Sorri AL, Lumme R, Hilesmaa V, Ylikorkala O. Low-dose aspirin in hypertensive pregnant women: effect on pregnancy outcome and prostacyclin-thromboxane balance in mother and newborn. *Br J Obstet Gynaecol* 1993, 100(9):809-815.

18. Wallenburg HC, Dekker GA, Makovitz JW, Rottman H. Low-dose aspirin prevents pregestation-induced hypertension and pre-eclampsia in angiotensin-sensitive primigravidae. *Lancet* 1986, (18471):1-3.

19. Bhutta ZA, Ali S, Cousens S, Ali TM, Haider BA, Razvi A, Okong P, Bhutta SZ, Black RE. *Alma-Ata: Rebirth and Revision 6 Interventions to address maternal, newborn, and child survival: what difference can integrated primary health care strategies make?* Lancet 2008, 372(9642):972-989.

20. Duley L, Hofmeyr GJ, Cawley J, Bahl R, Cousens S. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. *Cochrane Database Syst Rev* 2010, 11:CD000025.

21. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, et al. Grading of evidence and strength of recommendations. *BMJ* 2004, 328(7454):1490.

22. Walker N, Fischer-Walker C, Bryce J, Bahl R, Cousens S, Standards for CHEERG reviews of intervention effects on child survival. *Int J Epidemiol* 2010, 39(5):121-31.

23. Hofmeyr GJ, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. *Cochrane Database Syst Rev* 2006, 3:CD001059.
44. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 1994, 343(8898):619-629.

45. Michael CA, W B: Low-dose aspirin in the prevention of pre-eclampsia: current evaluation. In Maternal physiology and pathology Low-dose aspirin in the prevention of pre-eclampsia: current evaluation. Tech ES, Ratnam SS, Macnaughton MC 1993, 183.

46. Morris JM, Fay RA, Ellwood DA, Cook CM, Devanondj K. A randomized controlled trial of aspirin in patients with abnormal uterine artery blood flow. Obstet Gynecol 1996, 87(1):74-78.

47. Rogers MS, Fung HY, Hung CY. Calcium and low-dose aspirin prophylaxis in women at high risk of pregnancy-induced hypertension. Hypertens Pregnancy 1999, 18(2):165-172.

48. Wang Z, Li W. A prospective randomized placebo-controlled trial of low-dose aspirin for prevention of intra-uterine growth retardation. Chin J Obstet Gynaecol 1996, 10(9):238-242.

49. Ebrahify A, M Marzook, Yousuf D. Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery doppler ultrasound at 14-16 weeks pregnancy: randomized controlled clinical trial. Croatian Medical Journal 2005, 46:826.

50. Valpicelli T, D'Anto V, Faticato A, Galante L, Civitillo RM, Rappa C. Gestospiro 1999, 158:178-182.

51. Hermeda RC, A D, Iglesias M, Mojon A, Silva J, Uceda R. Time-dependent effects of low dose aspirin administration on blood pressure in pregnant women. Hypertension 1997, 30:589.

52. Ramayya C, Miga HA. Low dose aspirin in prevention of pregnancy-induced hypertension in primigravidae at the Muhimbili Medical Center, Dar es Salaam. East Afr Med J 1995, 72(11):690-693.

53. Carbis S, Sibai B, Hauht L, Lindeheiner MD, Kedassow M, Thom E, VanDorsten P, Landon M, Paul R, Miodownik M, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1998, 338(11):701-705.

54. Ross-Echeler CA, E Y, Molina L, Nova D. Synergetic use of aspirin, fish oil and vitamins C and E for the prevention of pre-eclampsia. 2000, 19:10.

55. JM B: Prevention of hypertensive disorders of pregnancy with calcium supplementation. 8th World Congress on Hypertension in Pregnancy; 1992 November 8-12, Buenos Aires, 1991.

56. Kumar A, Devi SG, Batra S, Singh C, Shukla DK. Calcium supplementation for the prevention of pre-eclampsia. Int J Gynaecol Obstet 2009, 104(1):32-36.

57. Villar J, A AH, Menaldini M, Mathali M, Ali M, Zawalaka N, et al: World Health Organisation randomized trial of calcium supplementation among low calcium intake pregnant women. American Journal of Obstetrics and Gynecology 2006, 194:69.

58. Kihalhe S, Z M, Carrara W, Paula FJ, Sabagba E, Neme B. Comparative study of chronic hypertensive pregnant women treated and non-treated with pindolol. Ginecologia e Obstetricia Brasileira 1985, 8:85.

59. DJ N: Evaluation of the use of Verapamil with non-serious form of chronic vascular hypertension disease during pregnancy Doctoral Thesis. 2000.

60. Flouin PF, Breat G, Lulco J, Dalle M, Keller ME, Goujon H, Berchel C. A randomized comparison of early with conservative use of antihypertensive drugs in the management of pregnancy-induced hypertension. Br J Obstet Gynaecol 1990, 97(2):134-141.

61. Blake S, MacDonald D. The prevention of the maternal manifestations of pre-eclampsia by intensive antihypertensive treatment. Br J Obstet Gynaecol 1991, 98(3):244-248.

62. Bott-Kanner G, H M, Friedman S, Boner G, Ovdava J, Merlob P, et al. Antihypertensive therapy in the management of hypertension in pregnancy - a clinical double-blind study of pindolol. Clinical and Experimental Hypertension 1992, 81:207.

63. Gruppo di Studio Ipertensione in Gravidanza: Nifedipine versus expectant management in mild to moderate hypertension in pregnancy. Gruppo di Studio Ipertensione in Gravidanza. Br J Obstet Gynaecol 1998, 105(7):718-722.

64. Odendaal HJ, S L, Patterson RC. Prasozin for the treatment of hypertension in pregnancy: a randomized control trial. In Oxford Database of Perinatal Trials, Version 12. Oxford: Oxford University Press; Autumn Chalmers I 1991, Disk Issue 6.

65. Wichman K, Ryden G, Karlborg BE. A placebo controlled trial of metoprolol in the treatment of hypertension in pregnancy. Scand J Clin Lab Invest Suppl 1984, 169:90-95.

66. Higestedt S, Lindeberg S, Axelsson O, Lindmark G, Rane A, Sandstrom B, Lindberg B. A prospective controlled trial of metoprolol-hydralazine treatment in hypertension during pregnancy. Acta Obstet Gynecol Scand 1985, 64(6):505-510.

67. Redman CW. Fetal outcome in trials of antihypertensive treatment in pregnancy. Lancet 1976, 2(7989):753-756.

68. Walker I, C A, Erwin L, Calder AA. Labetalol in pregnancy-induced hypertension: fetal and maternal effects. In International Congress Series 591 Amsterdam: Excerpta Medica Reilly A, Symonds EM 1982, 148.

69. Rubin PC, Butters L, Clark DM, Reynolds B, Sumner DJ, Steedman D, Low RA, Reid JL. Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. Lancet 1983, 1(8322):431-434.

70. Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ 1990, 301(6752):587-589.

71. Cruickshank DJ, R A, Campbell DM, MacGillivray I. Maternal obstetric outcome measures in a randomised controlled study of labetalol in the treatment of hypertension. Scand J Clin Lab Invest 1991, 185:333.

72. Sibai BM, Gonzalez AR, Mabie WC, Moretti M. A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term. Obstet Gynecol 1987, 70(3 Pt 1):323-327.

73. Sibai BM, Barton JR, Aki S, Sainoglu C, Mercer BM. A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term. Am J Obstet Gynecol 1992, 167(4 Pt 1):879-884.

74. Rosenfeld J, Bott-Kanner G, Boner G, Nirenkonk A, Friedman S, Ovdava J, Merlob P, Reisner S, Parar E, Zmora E, et al. Treatment of hypertension during pregnancy with hydralazine monotherapy or with combined therapy with hydralazine and pindolol. Eur J Obstet Gynecol Reprod Biol 1986, 22(4):197-204.

75. Parand E, Holberg G, Mazur M, Zmora E, Inler V. Beta-adrenergic blocking agents in the treatment of pregnancy-induced hypertension. Int J Clin Pharmacol Ther 1995, 33(2):119-123.

76. Catalano D, E S, Polillo F, Aiscione L, Russo C, De Santi B, et al. Evaluation of nifedipine monotherapy in the management of pregnancy hypertension. Giornale Italiano Di Ostetricia e Ginecologia 1997, 6:373.

77. Elhassan EM, Mirghani OA, Habour AB, Adam I. Methyldopa versus no drug treatment in the management of mild pre-eclampsia. Br J Obstet Gynaecol 1992, 99(12):172-175.

78. Leather HM, Humphreys DM, Baker P, Chadd MA. A controlled trial of hypertensive agents in hypertension in pregnancy. Lancet 1968, 2(7566):488-490.

79. Pichle CJ, Brughton Pipkin F, Symonds EM. A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension. Br J Obstet Gynaecol 1992, 99(12):964-968.

80. Weitz C, Khouzami V, Maxwell K, Johnson JW. Treatment of hypertension in pregnancy with methyldopa: a randomized double blind study. Int J Gynaecol Obstet 1987, 25(1):35-40.

81. Arias F, Zamora J. Antihypertensive treatment and pregnancy outcome in patients with mild chronic hypertension. Obstet Gynecol 1979, 53(4):489-494.

82. Altman D, Carroll G, Duley L, Farell B, Moodley J, Neilson J, Smith D. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002, 359(9221):1871-1890.

83. Moodley J, M J. Pharmacologic anticonvulsant therapy in hypertensive crises of pregnancy - the need for a large randomized trial. 1994, 13:245-252.

84. Coetzee EJ, Dommsie J, Anthony J. A randomised controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia. Br J Obstet Gynaecol 1998, 105(3):303-303.

85. Livingston JC, Livingston LW, Ramsey R, Mabie BC, Sibai BM. Magnesium sulfate in women with mild preeclampsia: a randomized controlled trial. Obstet Gynecol 2003, 101(2):217-220.

86. Wiltt AG, Friedman SA, Sibai BM. The effect of magnesium sulfate therapy on the duration of labor in women with mild preeclampsia at...
term: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol 1997, 176(3):623-627.

87. Chen FP, Chang SD, Chu KK: Expectant management in severe preeclampsia: does magnesium sulfate prevent the development of eclampsia? Acta Obstet Gynecol Scand 1995, 74(3):181-185.

88. Lawn JE, Yakob MY, Haws RA, Soomro T, Darmstadt GL, Bhutta ZA: 3.2 million stillbirths: epidemiology and overview of the evidence review. BMC Pregnancy Childbirth 2009, 9(Suppl 1):S2.

89. Mbah AK, Ailo AP, Marty PJ, Bruder K, Whiteman VE, Salihu HM: Preeclampsia in the first pregnancy and subsequent risk of stillbirth in black and white gravidas. Eur J Obstet Gynecol Reprod Biol 2010, 149(2):165-169.

90. Miller EC, Cao H, Wen SW, Yang Q, Lafleche J, Walker M: The risk of adverse pregnancy outcomes is increased in preeclamptic women who smoke compared with nonpreeclamptic women who do not smoke. Am J Obstet Gynecol 2010, 203(4):334 e331-338.

91. Onyiruaka AN: Analysis of stillbirths in a Nigerian mission hospital. Nig Q J Hosp Med 2009, 19(1):27-31.

92. Hossain N, Khan N, Khan NH: Obstetric causes of stillbirth at low socioeconomic settings. J Pak Med Assoc 2009, 59(11):744-747.

doi:10.1186/1471-2458-11-S3-S6
Cite this article as: Jabeen et al: Impact of interventions to prevent and manage preeclampsia and eclampsia on stillbirths. BMC Public Health 2011 11(Suppl 3):S6.